This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Chong-Chi Chiu, Department of General Surgery, Chi Mei Medical Center, Liouying 73657 and Tainan 71004, Taiwan
Chong-Chi Chiu, Department of Electrical Engineering, Southern Taiwan University of Science and Technology, Tainan 71005, Taiwan
Chao-Jung Tsao, Department of Oncology, Chi Mei Medical Center, Liouying 73657, Taiwan
Jhi-Joung Wang, Department of Medical Research, Chi Mei Medical Center, Tainan 71004, Taiwan
Jhi-Joung Wang, AI Biomed Center, Southern Taiwan University of Science and Technology, Tainan 71005, Taiwan
Yutaka Yonemura, Peritoneal Surface Malignancy Center, Kishiwada Tokushukai Hospital, Kishiwada, Osaka 596-8522, Japan
Author contributions: All authors participated in the writing and editing of the manuscript.
Supported bygrant from Chi Mei Medical Center, Liouying, Taiwan, No. CLFHR10606.
Conflict-of-interest statement: All authors declare no competing financial interests.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Received: December 25, 2018 Peer-review started: December 25, 2018 First decision: March 5, 2019 Revised: March 11, 2019 Accepted: April 19, 2019 Article in press: April 19, 2019 Published online: May 21, 2019 Processing time: 147 Days and 16.1 Hours
Abstract
Gastric cancer-associated peritoneal carcinomatosis leads to a poor prognosis and low quality of life. The current systemic chemotherapy processes cannot effectively improve survival. Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used as an alternative treatment to control this disease through recurrence prevention, definitive therapeutic modality, and symptom palliation. Although HIPEC has been demonstrated to yield favorable results mainly in some Asian studies, widespread adoption of this treatment is still debatable before larger prospective randomized controlled clinical trials confirm its effectiveness.
Core tip: Peritoneal carcinomatosis associated with gastric cancer leads to poor clinical outcomes and low quality of life. Hyperthermic intraperitoneal chemotherapy can potentially be used for the control of this disease.
